Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | MicrobiomeTrials← Back to trialsNCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-10-22Est. Completion: 2031-05-31
Enrollment target: 18 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Soft Tissue Sarcoma
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibo…
Duarte, United StatesCompleted Dec 11, 2025
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial CarcinomaAnogenital CancerHead and Neck (HNSCC)Cutaneous Squamous Cell Carcinoma (CSCC)Cervical Squamous Cell Carcinoma
ER+ Breast Cancer
Leiomyosarcoma (LMS)
Undifferentiated Pleomorphic Sarcoma (UPS)
Pancreatic Cancer Metastatic
Small Cell Lung Cancer
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA …
Los Angeles, United StatesCompleted Mar 17, 2026
Leiomyosarcoma
The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side …
Basking Ridge, United StatesEst. completion Apr 2029